1 Impact of interventions on mpox transmission during the 2022 outbreak in Canada: a

2 mathematical modeling study of three different cities

- Fanyu Xiu¹, Carla Doyle¹, Jorge Luis Flores Anato¹, Jesse Knight^{2,3}, Linwei Wang², Joseph 3
- Cox^{1,4}, Daniel Grace⁵, Trevor A. Hart^{5,6}, Terri Zhang⁶, Shayna Skakoon-Sparling^{6,7}, Milada 4
- Dvorakova⁴, Rita Shahin^{5,8}, Herveen Sachdeva^{5,8}, Nathan Lachowsky⁹, Hind Sbihi^{10,11}, Darrell 5
- H.S. Tan^{3,4,12}, Michael A. Irvine^{10,13,14}, Sharmistha Mishra^{2,3,5,12}, Mathieu Maheu-Giroux^{1‡} 6

7 **Author Affiliations:**

- 8 1. Department of Epidemiology and Biostatistics, McGill University, Montréal, QC, 9 Canada.
- 10 2. MAP Centre for Urban Health Solutions, Unity Health Toronto, ON, Canada.
- 3. Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada. 11
- 4. Research Institute of the McGill University Health Centre, Montréal, OC, Canada, 12
- 13 5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
- 6. Department of Psychology, Toronto Metropolitan University, Toronto, ON, Canada. 14
- 15 7. Department of Psychology, University of Guelph, Guelph, ON, Canada.
- 8. Toronto Public Health, ON, Canada. 16
- 17 9. School of Public Health and Social Policy, University of Victoria, Victoria, BC, Canada
- 10. Data and Analytic Services, British Columbia Centre for Disease Control, Vancouver, 18 19 BC, Canada.
- 20 11. School of Population and Public Health, University of British Columbia, Vancouver, BC, 21 Canada.
- 22 12. Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, 23 Canada.
 - 13. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
- 25 14. Department of Statistics, University of British Columbia, Vancouver, BC, Canada.
- 26 27 Abstract: 239 words
- 28 Main text: 3,250 words
- 29

24

30 [‡]Corresponding author:

- Mathieu Maheu-Giroux, ScD 31
- 32 Department of Epidemiology and Biostatistics,
- 33 School of Population and Global Health
- McGill University 34
- 35 2001 Avenue McGill College (Suite 1200),
- 36 Montréal, QC, Canada,
- 37 H3A 1G1
- 38 E-mail: mathieu.maheu-giroux@mcgill.ca
- 39 Phone: (+1) 514-398-5110
- 40 **Key words:** mpox; monkeypox; mathematical model; men who have sex with men; vaccination;
- 41 contact tracing; behavioural change; Modified vaccinia Ankara; MVA-BN.

⁴²

43 Abstract

44 Background: The 2022-2023 global mpox outbreak primarily affected gay, bisexual, and other 45 men who have sex with men (GBM). It was met with swift community and public health 46 responses. The relative impact of GBM's reductions in sexual partners, contact tracing/isolation, 47 and vaccination on transmission in Canadian cities remain unknown.

48 **Methods:** We estimated changes in sexual behaviours during the outbreak using 2022 data from 49 the Engage Cohort Study which recruited self-identified GBM in Montréal, Toronto, and 50 Vancouver (n=1,445). The numbers of sexual partners in the past 6 months (P6M) were modeled 51 using negative binomial regressions. A transmission-dynamic compartmental model was 52 calibrated to surveillance data. We estimated the averted fraction of new infections attributable to 53 reductions in sexual partners, contact tracing/isolation, and first-dose vaccination, versus an 54 unmitigated epidemic scenario, in each of the three cities. 55 **Results:** The empirical estimates of sexual behaviours changes were imprecise: 20% (RR=0.80;

56 95% credible intervals [95%CrI]: 0.47-1.36) fewer sexual partners among those reporting \leq 7 57 partners (P6M) and 33% (RR=0.67; 95%CrI: 0.31-1.43) fewer among those with >7 partners 58 (P6M). Compared to the unmitigated epidemics, we estimated that the three interventions 59 combined avert 46%-58% of cases. Reductions in sexual partners, contact tracing/isolation 60 prevented approximately 12% and 14% of cases, respectively. Vaccination's effect varied across 61 cities by start date and coverage, with 21%-39% mpox infections prevented.

62 **Conclusions:** Reduction in sexual activity, contact tracing/isolation, and vaccination all 63 contributed to accelerating epidemic control and infections averted. Early vaccination had the 64 largest impact.

65

66 Background

67 The 2022-2023 global mpox outbreak resulted in more than 90,000 infections across 110 68 historically non-endemic regions, including Canada; it also disproportionately impacted gay, 69 bisexual, and other men who have sex with men (GBM) [1]. Unlike historically reported cases in 70 Central and West Africa, the recent global outbreak was sustained due to human-to-human 71 transmission, primarily via sexual contacts [2]. From May 2022 to October 2023, 98% of 1,443 72 confirmed cases with available data in Canada, occurred among GBM [3]. Over 70% of the 73 reported cases were concentrated in Montréal (Québec), Toronto (Ontario), and Vancouver 74 (British Columbia), the country's three largest cities [4–6]. Mpox's cumulative incidences 75 among GBM were around 1% in all three cities, despite differences in timing of outbreaks and 76 interventions [7].

On May 19th, 2022, the first confirmed mpox case in Canada was reported in Montréal, 77 78 the site of the first North American outbreak [8]. Cases in Toronto and Vancouver were respectively confirmed first on May 26th and June 6th of that year [8,9]. The outbreaks were met 79 80 with swift responses from community organizations, sexual health professionals, laboratorians, 81 and public health teams. The number of mpox cases peaked in all three cities from late-June to 82 mid-July 2022 and declined thereafter, alongside the roll-out of public health interventions [3]. 83 Various factors that govern the underlying transmission dynamics could have contributed to 84 reductions in transmission, including saturation of groups at high risk of infection [10–13], 85 changes in sexual behaviours following community outreach [14–16], contact tracing and 86 isolation of traced contacts by local public health units [17,18], and use of vaccination [19,20].

87 Previous work showed that the effective reproduction number (i.e., \Box_{t} : the average 88 number of secondary infections from one infectious individual where some people are no longer 89 susceptible) could drop below 1 if even a small proportion (<2%) of GBM with the highest 90 levels of sexual activity acquired immunity [7,11]. In Canada, public health authorities partnered 91 with community-based organizations to amplify messaging about mpox prevention by reducing 92 sexual partner numbers, prevention, testing, and vaccination on digital platforms and at gathering 93 places [21,22]. Online surveys among convenience samples of GBM in the United Kingdom and 94 the United States found that nearly half of interviewed GBM reported reducing their sexual 95 partner numbers and visits to sex-on-premises venues after the onset of the mpox outbreak 96 [15,16]. It remains uncertain if, and to which extent, GBM living in Canada similarly adapted

97 their sexual behaviours in response to the mpox outbreaks, and what impact this had on the 98 course of the epidemics.

99 Local health authorities conducted case and contact management to identify source 100 infections and encouraged exposed symptomatic contacts to self-isolate [23]. In Montréal, 20% 101 of contacts of confirmed cases were successfully traced/notified since late May 2022, resulting 102 from the high number of anonymous sexual contacts [4,24]. Identified contacts were advised to 103 self-monitor for symptoms and based on exposure risks, advised to receive post-exposure 104 prophylaxis (PEP) using the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine 105 [4,23,24].

MVA-BN is a third-generation smallpox vaccine that offers cross-protection against the mpox virus [25,26]. In early June 2022, one-dose of vaccine for pre-exposure prophylaxis (PrEP) became available to individuals at high risk of exposure [5,24,27], including GBM who had sex with more than one partner and engaged in sexual contact in sex-on-premises venues [28]. As of mid-October 2022, approximately 24,000 first-doses in Montréal, and 35,000 in Toronto, of MVA-BN vaccines were administered [24,27]. In Vancouver, 18,000 first- and second-doses had been given over that same period [5].

113 Since mid-November 2022, case activity has been sporadic [3]. Understanding the impact 114 of the main interventions in Montréal, Toronto, and Vancouver could generate new evidence, 115 inform mpox prevention, and prioritize future public health actions. We aimed to evaluate the 116 relative contribution of a) changes in sexual partner numbers, b) contact tracing/isolation, and c) 117 first-dose vaccination on 2022 mpox outbreak dynamics among GBM in three different cities, 118 while considering potential saturation of infections within high-risk groups. Specifically, we 119 leveraged the Engage Cohort Study, a population-based study of GBM in the three cities, to 120 empirically evaluate changes in sexual partner numbers during the period of high mpox 121 transmission. We then developed a risk-stratified dynamic model of mpox transmission 122 calibrated to mpox case surveillance data, to retrospectively assess the impact of various 123 interventions on the final epidemic size, disentangling their unique contributions.

124 Methods

125 Data Source

126 The *Engage Cohort Study* is a prospective cohort of GBM in Montréal, Toronto, and 127 Vancouver. Detailed descriptions of *Engage* can be found elsewhere [29–32]. Briefly, eligible

participants were self-identified cisgender or transgender men living in one of the three cities, aged ≥ 16 years, reported sex with another man in the past 6 months (P6M), understood English and/or French, and provided written informed consent [33]. Participants were recruited during 2017-2019 in each city using respondent-driven sampling (RDS) with subsequent study followup visits every 6-12 months [34]. At each visit, participants completed an online questionnaire including questions about sexual behaviours.

134 Changes in number of sexual partners during the mpox epidemics

135 To estimate changes in self-reported number of all-type sexual partners, we first excluded 136 visits prior to 2022, given disruptions in sexual behaviours during the COVID-19 pandemic in 137 2020 and 2021 [7,35,36]. We defined the period over which mpox-driven behaviour changes could have occurred from May 19th, 2022 (first reported mpox case in Canada) to August 14th, 138 139 2022 (vaccination coverage >30% in all three cities). The latter date was chosen to ensure a 140 reasonable sample size and account for mpox vaccination scale-up. Using data from all 141 participants who had at least one visit in 2022, we fit a Bayesian negative binomial regression 142 model to the number of sexual partners in the P6M, with a random intercept for each participant. 143 We defined our exposure as the continuous fraction of the 6-month recall period that overlapped 144 with the period of potential behaviour changes (i.e., adjusting for attenuation given the long 145 recall period). We also included the following covariates: age (16-29, 30-39, 40-49, 50-59, ≥ 60 146 years), relationship status history (single/exclusive/open/unclear relationship at latest visit before 147 2022), HIV status (positive, negative/unknown), calendar month (continuous), and sexual 148 partnership history (≤ 7 or >7 male sexual partners in the P6M at the latest visit before 2022). We 149 then computed the relative change in sexual partner numbers (rate ratio, RR) during the mpox 150 outbreak by sexual partnership history, to examine potential effect modification. Details on 151 variable definitions and the regression model are available in the *Supplementary Methods*.

To assess the sensitivity of our results, we repeated the analysis using alternative categorizations of sexual partnership history (≤ 3 or >3, and ≤ 5 or >5 male sexual partners in the P6M). We used a different end point of the behaviour change period (July 14th, 2022) to assess the sensitivity to an alternative exposure definition. We used a Bayesian logistic regression model to study two alternate outcomes: visit to bathhouses and/or sex clubs at least once in the P6M (binary) and attendance at group sex events at least once in the P6M (binary).


158 All empirical data analyses were performed with *R* (4.3.2) [37], using the *RStan* (2.32.3) 159 [38] and *rstanarm* (2.26.1) [39] packages.

160 Dynamic model of mpox transmission

161 We developed a dynamic, deterministic compartmental model of mpox transmission and 162 control among a closed population of GBM. Surveillance data suggest that 30-39-year-olds, high 163 numbers of sexual partners, and living with HIV were associated with mpox diagnosis [3,40]. 164 We stratified the model into 5 age groups (16-29, 30-39, 40-49, 50-59, ≥ 60 years), 10 sexual 165 activity groups (representing 60%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, and 99.8% 166 percentiles in the distribution of P6M sexual partner numbers), and HIV status (positive, 167 negative/unknown). All GBM are assumed susceptible at the start of the outbreak, and they can 168 acquire mpox and transition into the exposed (but not yet infectious) compartment, depending on 169 a time-varying force of infection (*Figure 1*). The latter considers the mixing between GBM by 170 age, sexual activity, and HIV status. The age and HIV mixing were informed by previous studies 171 [41], and degree of assortativity by sexual activity was calibrated. Based on a previous analysis 172 [7], we allowed for underreporting and reporting delays [42,43]: 77%-86% of all infections were 173 estimated to be reported in the surveillance data.

174 In terms of interventions, community and public health messaging could have led to 175 potential behaviour changes. GBM's contact rates were allowed to vary using a rate ratio that 176 reflected potential reductions in sexual activity (as informed by a prior from the empirical 177 analysis above). Exposed GBM can be traced and isolated by local public health authorities. 178 Local public health authorities in Montréal suggested that 20% of contacts of reported cases were 179 traced [4,24]. We adjusted that 20% by the fraction of cases reported in each city and the fraction 180 of contacts traced before being infectious. Given limited vaccine supply, first-dose vaccination 181 coverage was maximized by delaying the administration of second doses [24]. We only modeled 182 first-dose vaccination, as it constituted >90% of vaccines administered before mid-October 2022 183 in all three provinces [5,24,27]. We used the age-specific weekly doses administered from 184 publicly available reports [4,5,24,27]. Vaccine effectiveness was modeled using a leaky-type 185 vaccination compartment-partially effective for all vaccinated, instead of fully effective for a 186 fraction vaccinated [44]. Values of model parameters are defined in *Table S2*. Model structure is 187 presented in *Figure 1* and details are in *Supplementary Methods*.

188 S^{ash}



189

190 Figure 1. Diagram of the compartmental flows of the deterministic model of mpox virus 191 transmission among gay, bisexual, and other men who have sex with men (GBM). a, s, h: 192 superscripts for age groups, sexual activity groups, and HIV status, respectively. The name of the 193 compartments refers to susceptible (S), exposed (E), infectious (I), removed (R), vaccinated (V), 194 and isolated (J). Removed refers to the state where GBM are no longer infectious, stopped 195 having sex, or developed natural immunity to mpox. Two other compartments are used to track 196 symptoms onset (O) and the case confirmation process (C). The main parameters are the 197 following: ψ_t : first-dose vaccination doses at time t; proportion of vaccinations received by 198 age groups; 1-vaccine effectiveness (assuming leaky type); : force of infection specific to 199 group a, s, h at time t; : rate of infectivity onset among exposed \approx (latent period)⁻¹; v_i: proportion traced and isolated among exposed at time t; : rate of removal among infectious 200 201 individuals who are not traced and isolated = $(effective infectious period)^{-1}$; rate of removal 202 among infectious individuals who are traced and isolated = $(self-isolation period)^{-1}$; the 203 reporting fraction (proportion of cases that are reported, calibrated parameter); : reporting delay. 204 Values of parameters are defined in *Table S2*.

205

7

206 Model calibration

We calibrated the model using mpox surveillance data, assuming all reported cases were among GBM [3–6,24,45]. The model was calibrated jointly for the three cities using a Bayesian sampling importance resampling and a negative binomial likelihood for daily numbers of total reported cases.

We cross-validated our models to the following outcomes (whenever available): the proportion of mpox cases who were among people living with HIV in Montréal, the age distribution of cases in Montréal and Toronto, and the age distribution of vaccines received in Montréal and Toronto.

215 Averted fraction of new infections from past interventions

Using the calibrated model, we evaluated the impacts on mpox transmission of 1) changes in number of sexual partners, 2) contact tracing/isolation, 3) first-dose vaccination, 4) all three measures combined, and 5) combinations of any two interventions. We estimated the impact using the cumulative averted fraction (AF) of new infections, calculated as the difference in the cumulative incidence between each of the interventions scenarios above divided by the counterfactual cumulative incidence corresponding to an unmitigated epidemic.

222 Sensitivity analysis for the averted fraction of new infections

223 First, we assessed the model sensitivity to our prior for the changes in sexual partner 224 numbers by fixing the RR to the point estimates found in the empirical analysis. Second, we 225 reduced the proportion of contacts traced from 20% to 15% and 10% to reflect potential non-226 disclosure of sexual contacts. Third, we examined the sensitivity of our results to vaccine 227 effectiveness by using the minimum and maximum of estimates from literature (35.8% and 228 86.0%, respectively) [46–52]. Finally, to directly compare the impact of vaccination in all three 229 cities, we examined a scenario where vaccination was initiated the same number of days after 230 detection of the first local cases and reached the same daily coverage, using Vancouver as the 231 reference since it had an earlier start of vaccination and achieved the highest vaccine coverage. 232 For the first three analyses, we re-calibrated the model and re-calculated the averted fractions.

The model was coded in R, using a C++ back-end [53], and solved using an Euler algorithm with a 6-hour time step. Additional details on methods can be found in the *Supplementary Methods*.

236 **Results**

237 Changes in numbers of sexual partners during the mpox epidemics

238 Out of 1,957 visits from participants that occurred during 2022, 424 visits partly overlapped with the potential behaviour change period (May 19th-August 14th, 2022). Although 239 240 imprecise, the results from the regression model were indicative of a decrease in sexual partners. 241 Specifically, we estimated a RR of 0.80 (95% Credible interval [CrI]: 0.47-1.36) and 0.67 242 (95% CrI: 0.31-1.43) among those with >7 (P6M) and \leq 7 sexual partners at their last visit before 243 2022 (Table 1). Summary statistics of the study population from Engage and the effect estimates 244 of covariates are presented in *Table S6* and *Table S7*. Sensitivity analyses are shown in *Table S8*. 245 The results on changes in visits to sex-on-premises venues and attendance of group sex were 246 inconclusive.

247

Table 1. Changes in the number of reported sexual partners in the past 6 months during

249 the period of mpox-driven potential behaviour changes among participants in the *Engage*

250	Cohort Study,	, by sexual partnership history.	
-----	---------------	----------------------------------	--

Numbers of sexual partners at the latest visit before 2022	Number of visits		RR (95%CrI)
	During Mpox	Rest of 2022	
	outbreak		
≤7 sexual partners	324	1211	0.80 (0.47, 1.36)
>7 sexual partners	100	322	0.67 (0.31, 1.43)

There were 424 visits for which the past 6 months recall period overlapped with the mpox epidemic. Among those, an average of 19% of the recall period was within the epidemic period. Models adjusted for months since January 1st, 2022 (1, 2, ..., 12; continuous), age (16-29, 30-39, 40-49, 50-59, \geq 60 years), relationship status history (single, exclusive relationship, open relationship, unclear), and HIV status (binary). *CrI* = credible interval; *RR* = rate ratio.


256 Model calibration

The city-specific models replicated the daily number of reported cases (*Figure 2*), with a slight overestimation of cases in Toronto during the Fall of 2022. Furthermore, the modelpredicted age distribution and HIV status of cases generally matched well with the one reported

from local surveillance data (*Figure S2*). The model slightly overestimated cases in the 16-29
age groups and underestimated those in the 30-39 groups in Montréal and Toronto. The posterior
parameter distributions for calibrated parameters are in *Table S9*.

263 Fraction of cases averted by interventions


264 In the three cities, we found that the outbreaks would have subsided without any 265 interventions, but with nearly 50% more infections (Figure 3). Combined, we estimated that the 266 three interventions averted 48% (35%-66%), 46% (34%-67%), and 58% (52%-69%) infections 267 in Montréal, Toronto, and Vancouver, respectively. The calibrated RR for changes in number of 268 sexual partners was 0.94 (95%CrI: 0.80-0.99) across sexual partnership history level defined 269 by >7 partners and 0.94 (0.70-0.99) among those defined by \leq 7 partners. The changes in number 270 of sexual partners moderately decreased transmission: the estimated AF was 15% (3%-34%) in 271 Montréal, 11% (2%-27%) in Toronto, and 10% (2%-22%) in Vancouver. Contact tracing averted 272 14% (12%-21%), 14% (12%-22%), and 14% (12%-16%) of infections in Montréal, Toronto, and 273 Vancouver, respectively. We estimated that first-dose vaccine coverage among GBM reached 44% 274 (Montréal), 45% (Toronto), and 58% (Vancouver) by mid-October 2022 (Figure S3). The 275 impact of vaccination varied according to vaccine coverage and the timing of vaccine campaign 276 initiation relative to the beginning of the outbreak. Vaccination averted 21% (16%-33%), 22% 277 (16%-41%), and 39% (35%-48%) of infections in Montréal, Toronto, and Vancouver, 278 respectively. The added effects of any combinations of two interventions were roughly equal to 279 the sum of their individual effects (Table S10).



280

281 Figure 2. Model-calibrated epidemic curves and observed mpox case data in Montréal (A),

Toronto (B), and Vancouver (C) during 2022. The reported case data (points) and model fits (curves) are presented up to 150 days after the first reported mpox cases in each city. The solid line is the median of the modeled cases, and the shaded area shows the 95% credible interval for the mean number of daily cases.



286

287 Figure 3. Model-predicted daily reported mpox cases in 2022 in Montréal, Toronto, and 288 Vancouver under observed interventions levels and scenarios with selected interventions. 289 The lines represent the median. The green lines and shaded area (95% credible intervals) 290 correspond to the observed epidemic curves in the three cities. The grey lines are the modeled 291 unmitigated epidemic. The blue lines are the epidemic curves with reduction in sexual partner 292 numbers alone, the purple lines are with contact tracing/isolation alone, and the maroon lines are 293 with first dose vaccination alone. Vertical dashed lines show the start of one-dose vaccination in each city: June 3rd, June 12th, and June 20th, 2022, in Montréal, Toronto, and Vancouver, 294 295 respectively. The estimates for intervention scenarios were shown in Table S10.

296

297 Sensitivity analyses for the fraction of cases averted by interventions

298 Fixing the values of the RR for the reduction in numbers of sexual partners to the point 299 estimates from the empirical behavior change analysis did not replicate the epidemic well. This 300 suggests that such parameters are not compatible with the observed outbreak trajectories. The 301 fraction of cases averted by contact tracing was reduced to 10%-11% and 7% when using a 302 proportion of 15% and 10% of cases traced, respectively (Table S10). First-dose vaccination 303 prevented 14%-29% of cases when using 35.8% vaccine effectiveness (1-dose). Conversely, 304 assuming 86.0% vaccine effectiveness, the number of cases prevented increased to 38%-59%. 305 Finally, standardizing the start of vaccination and vaccine coverage to Vancouver resulted in a 306 similar fraction of cases averted by vaccination in the three cities (38%-41%).

307 Discussion

308 The 2022-2023 mpox outbreak was met with swift community and public health 309 responses in Canada, inspired by GBM communities' decades-long fight against HIV. Using 310 cohort data from a representative sample of urban GBM in Canada and a calibrated risk-stratified 311 dynamic model of mpox transmission, we estimated that, altogether, behaviour changes, contact 312 tracing/isolation, and vaccination averted 46%-58% of cases among GBM in Canada's three 313 largest cities. Among these, vaccination had the largest impact on averted cases despite moderate 314 coverage of first doses (44%-58%) among GBM. Vaccines alone averted an estimated 21%-39% 315 of new infections, depending on the city. Our findings support implementing targeted 316 vaccination quickly and at-scale if localized epidemics resurge and continuing immunization 317 among GBM with multiple sexual partners. This measure is relevant given current low coverage 318 of the second doses, higher vaccine effectiveness conferred by two-doses [47], current absence 319 of vaccination clinics in the cities, and localized epidemic resurgence in Toronto in early 2024 320 [45].

Our analysis, based on a large, population-based cohort, suggests that GBM may have changed sexual behaviours to have fewer sexual partners during the mpox outbreak. However, the estimate was highly uncertain, particularly given the drop in sexual partner numbers that had already occurred due to previous COVID-19 lockdowns [36], precluding a definite conclusion from the empirical analysis. Nevertheless, our calibrated dynamic models suggest that small declines in partner numbers are compatible with the observed epidemics. These averted 10%-15% of cases across the three cities.

Assuming that 20% of contacts were traced (as reported from Montréal), tracing/isolation of exposed cases averted 14% of infections in the three cities. This impact was sensitive to the proportion of traced sexual contacts. Lack of contact information reported by cases, largely due to anonymous partnering, limited the proportion of contacts traced and isolated.

As of mid-October 2022, we estimated that the large-scale vaccination of first-dose of MVA-BN vaccine attained coverage of 44%, 45%, and 58% among GBM in Montréal, Toronto, and Vancouver, respectively [5,24,27]. Assuming 51.5% vaccine effectiveness, first-dose vaccination averted 39% of infection in Vancouver (95%CrI: 35%-48%), 22% in Toronto (95%CrI: 16%-41%) and 21% in Montréal (95%CrI: 16%-33%). High vaccine coverage in Vancouver may explain the higher impact in that city (*Table S10*).

338 Despite these notable impacts, the mpox outbreaks could have waned without any of the 339 three interventions. This is consistent with the saturation of "core groups", resulting in the 340 accumulation of infection-derived immunity against mpox and, ultimately, the epidemic's 341 downturn. However, it is likely that, the community and public health responses greatly 342 accelerated the decline in incidence, as has been found in other settings [10,12].

343 Our results should be interpreted considering several limitations. First, we had limited 344 information on contact tracing/isolation and it is difficult to effectively model this intervention 345 using compartmental models. We used an approximation to estimate the proportion of publicly 346 traced cases that would be isolated before onset of infectiousness. However, case self-347 notification of partners was not captured by contact tracing data, which means we could have 348 underestimated the impact of contact tracing/isolation. Second, we assumed that GBM had 349 initially no prior immunity against mpox. However, some GBM born before smallpox 350 vaccination stopped in Canada in 1972 and those that immigrated from certain countries could 351 have previously received smallpox vaccines [54,55]. This should not change our results much 352 because people aged >50 years old represented only <14% all cases in Canada [3]. Finally, 353 vaccination was age-specific, but it did not fully reflect prioritization by partner numbers and 354 HIV status, whereas individuals at higher risk of mpox acquisition may have been more likely to 355 receive vaccines, meaning the effect of vaccination could have been underestimated.

The strengths of this study include the use of data from a large population-based cohort to inform model parameterization and statistical analyses. This approach allowed us to empirically explore the impact of behaviour changes. Second, we accounted for balanced mixing by age

359 groups, sexual activity groups, and HIV status in the mpox transmission model, all strongly 360 associated with mpox diagnoses in surveillance data [3,56]. Finally, we calibrated the model in a 361 Bayesian framework, ensuring that parameter uncertainty is reflected in our model estimates, and 362 cross-validated our model predictions.

363 Conclusion

GBM in Montréal, Toronto, and Vancouver may have decreased sexual partnering during the transmission period of the 2022 mpox outbreak, which alongside contact tracing/isolation, contributed to averting mpox infections. Early vaccination was key to reducing the number of mpox infections. While mpox outbreaks in Canada could have eventually subsided without intervention, 50% more cases could have been infected, leading to unnecessary harms and potentially serious health consequences.

370

371 **Declarations**

372 Ethics

373 The Research Institute of the McGill University Health Centre and the Research Ethics 374 Office of the Faculty of Medicine and Health Sciences, McGill University (A06-M32-23B), 375 Toronto Metropolitan University (REB #2016-113), the University of Toronto (protocol 376 #00033527), St. Michael's Hospital (REB #17-043), the University of Windsor (REB #33443), 377 the University of British Columbia (H16-01226), Providence Health Care (H16-01226), the 378 University of Victoria (H16-01226), and Simon Fraser University (H16-01226) provided ethics 379 approvals for the Engage Cohort Study. The Research Ethics Office of the Faculty of Medicine 380 and Health Sciences at McGill University approved the secondary analyses of the data in this 381 study.

382 Acknowledgments

The Engage Cohort Study is led by Principal Investigators in Montreal by Joseph Cox and Gilles Lambert; in Toronto by Trevor A. Hart & Daniel Grace; and in Vancouver by Jody Jollimore, Nathan Lachowsky, and David Moore. More information about the Engage Cohort Study can be found here: <u>https://www.engage-men.ca.</u> The authors would like to thank the *Engage* study participants, office staff, and community engagement committee members, as well as our community partner agency, *RÉZO*.

389 Author contribution

390 FX, CD, SM, MI, and MM-G contributed to the conception and design. JC, DG, TAH, 391 MD, NJL, SSS, and SM were involved in the design, data collection, and data management of 392 the Engage Cohort Study. Analyses were performed by FX, with support from CD, JLFA, and 393 MM-G. LW, JK, MI, and SM provided input on preliminary methods discussions. JK and LW 394 developed the preferential mixing matrices, and JK coded the algorithm. The manuscript was 395 drafted by FX. All authors reviewed the manuscript for important intellectual content. Overall 396 supervision for this project was provided by MM-G. All authors approved the final manuscript. 397 The Engage study is led by the following principal investigators (in alphabetical order): Joseph

Cox, Daniel Grace, Trevor Hart, Jody Jollimore, Nathan Lachowsky, Gilles Lambert, and DavidMoore.

400 **Conflict of interest**

401 JC reports research grants from Gilead Sciences Canada and ViiV Healthcare, all outside 402 of the submitted work. MM-G reports contractual arrangements from the World Health 403 Organization, the Joint United Nations Programme on HIV/AIDS (UNAIDS), and the Public 404 Health Agency of Canada, all outside of the submitted work. TAH reports educational grants 405 from being an Advisory Committee member for the Canadian Institutes of Health Research 406 (CIHR)'s Institute of Infection and Immunity and funds for community engagement events from 407 ViiV Healthcare and Gilead Sciences Canada, all outside of the submitted work. DHST's 408 institution has received investigator-initiated grants from Abbvie and Gilead, and support for 409 participation in clinical trials sponsored by Glaxo Smith Kline. All other authors report no 410 conflict of interest.

411 Funding

Engage/Momentum II is funded by the Canadian Institutes for Health Research (CIHR, #TE2-138299, #FDN-143342, and #PJT- 153139), the CIHR Canadian HIV/AIDS Trials Network (#CTN300), the Canadian Foundation for AIDS Research (CANFAR, #Engage), the Ontario HIV Treatment Network (OHTN, #1051), the Public Health Agency of Canada (Ref: 4500370314), Toronto Metropolitan University, Canadian Blood Services (#MSM2017LP-OD), and the Ministère de la Santé et des Services sociaux (MSSS) du Québec. The *Engage* study data is available upon request to the *Engage* team.

This work was supported by the *Canadian Network for Modelling Infectious Diseases* (CANMOD) to SM, MI, and MM-G, grants from the *Canadian Institutes of Health Research* (CIHR, #495171) to MI, SM, HS, and MM-G, and grants from the University of Toronto Emerging Infections and Pandemic Consortium Mpox Rapid Research Response to SM and DHST. MM-G's research program is funded by a Canada Research Chair (Tier 2) in *Population Health Modelling*. FX acknowledges studentships from the *McGill Center for Viral Diseases* and the *McGill Faculty of Medicine and Health Sciences*. TAH received support from a Chair in Gay

426 and Bisexual Men's Health from the Ontario HIV Treatment Network. SM's research program is 427 funded by a Canada Research Chair (Tier 2, CRC Number 950-232643) in Mathematical 428 Modelling and Program Science. DG's research program is funded by a Canada Research Chair 429 (Tier 2) in Sexual and Gender Minority Health. DHST is supported by a Canada Research Chair 430 (Tier 2) in HIV Prevention and STI Research. JK acknowledges support from the Natural 431 Sciences and Engineering Research Council of Canada Doctoral Award. NL is supported with 432 Scholar Awards from the Michael Smith Foundation for Health Research (#5209, #16863). SS-S 433 is supported by a CIHR postdoctoral fellowship award. The funders had no role in the study 434 design, data collection, and analysis, decision to publish, or preparation of the manuscript.

435 Software and source code

The model package and code for analyses are available on a GitHub repository (https://github.com/pop-health-mod/mpox-intervention).

438 **References**

- CDC. 2022 Mpox Outbreak Global Map | Mpox | Poxvirus. 2023. Available at: https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html. Accessed 3 February 2024.
- Laurenson-Schafer H, Sklenovská N, Hoxha A, et al. Description of the first global
 outbreak of mpox: an analysis of global surveillance data. The Lancet Global Health 2023;
 11:e1012–e1023.
- 445 3. Public Health Agency of Canada. Mpox (monkeypox) epidemiology update Canada.ca.
 446 Available at: https://health-infobase.canada.ca/mpox/. Accessed 3 February 2024.
- 447 4. Signor C, Allard R, Ngambo G, et al. Flash Vigie Septembre 2022. Available at:
 448 https://publications.msss.gouv.qc.ca/msss/fichiers/flashvigie/FlashVigie_vol16_no4.pdf.
- 449 5. BCCDC. Mpox surveillance report. 2023. Available at: http://www.bccdc.ca/Health-Info450 Site/Documents/Monkeypox/Epidemiological_Summary/Mpox_Surveillance_20230109.pd
 451 f. Accessed 16 November 2023.
- 452 6. Public Health Ontario. Mpox in Ontario: May 1, 2022 to July 31, 2023. 2023. Available at:
 453 https://www.publichealthontario.ca/-/media/Documents/M/2022/monkeypox454 episummary.pdf?rev=ccdc118970104a4c9e634eb46e52839c&sc_lang=en.
- 455
 456
 456
 456
 457
 457
 458
 458
 2024; 229:S293–S304.
- 8. BCCDC. Mpox: Information for healthcare providers about mpox. Available at:
 http://www.bccdc.ca/health-professionals/clinical-resources/mpox. Accessed 11 February
 2024.
- 462 9. Toronto Public Health. Toronto Public Health confirms first case of monkeypox City of
 463 Toronto. Available at: https://www.toronto.ca/news/toronto-public-health-confirms-first464 case-of-monkeypox/. Accessed 11 February 2024.
- 465 10. Zhang X-S, Mandal S, Mohammed H, et al. Transmission dynamics and effect of control
 466 measures on the 2022 outbreak of mpox among gay, bisexual, and other men who have sex
 467 with men in England: a mathematical modelling study. Lancet Infect Dis 2023; 24:65–74.
- 468 11. Murayama H, Pearson CAB, Abbott S, et al. Accumulation of immunity in heavy-tailed
 469 sexual contact networks shapes mpox outbreak sizes. J Infect Dis 2023; 229:59–63.
- 470 12. Brand SPC, Cavallaro M, Cumming F, et al. The role of vaccination and public awareness
 471 in forecasts of Mpox incidence in the United Kingdom. Nat Commun 2023; 14:4100.

472 13. Xiridou M, Miura F, Adam P, Op de Coul E, de Wit J, Wallinga J. The fading of the mpox
473 outbreak among men who have sex with men: a mathematical modelling study. J Infect Dis
474 2023; Available at: https://doi.org/10.1093/infdis/jiad414. Accessed 9 November 2023.

- 475 14. Torres TS, Silva MST, Coutinho C, et al. Evaluation of Mpox Knowledge, Stigma, and
 476 Willingness to Vaccinate for Mpox: Cross-Sectional Web-Based Survey Among Sexual and
 477 Gender Minorities. JMIR Public Health and Surveillance 2023; 9:e46489.
- 478 15. Ogaz D, Enayat Q, Brown JR, et al. Mpox diagnosis history, behavioural risk modification, and vaccination uptake in gay, bisexual, and other men who have sex with men in the UK:
 480 findings from a large, online community cross-sectional survey (RiiSH-Mpox) undertaken
 481 November/December 2022. 2023; :2023.05.11.23289797. Available at:
- 482 https://www.medrxiv.org/content/10.1101/2023.05.11.23289797v1. Accessed 4 February 483 2024.
- 484 16. Delaney KP. Strategies Adopted by Gay, Bisexual, and Other Men Who Have Sex with
 485 Men to Prevent Monkeypox virus Transmission United States, August 2022. MMWR
 486 Martel Wilde Day 2022, 71 Assilable straight and the straight straight
- 486 Morb Mortal Wkly Rep **2022**; 71. Available at:
- 487 https://www.cdc.gov/mmwr/volumes/71/wr/mm7135e1.htm. Accessed 23 April 2023.
- 488 17. Yuan P, Tan Y, Yang L, et al. Assessing transmission risks and control strategy for
 489 monkeypox as an emerging zoonosis in a metropolitan area. J Med Virol 2023; 95:e28137.
- 490 18. Chitwood MH, Kwon J, Savinkina A, Walker J, Bilinski A, Gonsalves G. Estimated
 491 Testing, Tracing, and Vaccination Targets for Containment of the US Mpox Outbreak.
 492 JAMA Netw Open 2023; 6:e2250984.
- Clay PA, Asher JM, Carnes N, et al. Modelling the impact of vaccination and sexual
 behaviour adaptations on mpox cases in the USA during the 2022 outbreak. Sex Transm
 Infect 2023; Available at: https://sti.bmj.com/content/early/2023/12/02/sextrans-2023055922. Accessed 5 February 2024.
- Lin Y-C, Wen T-H, Shih W-L, Vermund SH, Fang C-T. Impact of vaccination and highrisk group awareness on the mpox epidemic in the United States, 2022-2023: a modelling
 study. EClinicalMedicine 2024; 68:102407.
- Public Health Agency of Canada. Government of Canada partners with community-based
 organizations to address monkeypox outbreak. 2022. Available at:
 https://www.canada.ca/en/public-health/news/2022/07/government-of-canada-partners-
- with-community-based-organizations-to-address-monkeypox-outbreak.html. Accessed 3
 March 2024.
- 505 22. Tan DHS, Awad A, Zygmunt A, et al. Community mobilization to guide the public health
 506 response during the 2022 Ontario mpox outbreak: A brief report. Open Forum Infectious
 507 Diseases 2024;
- 508 23. Public Health Agency of Canada. Mpox (monkeypox): Public health management of cases
 509 and contacts in Canada. 2022. Available at: https://www.canada.ca/en/public-

- 510 health/services/diseases/mpox/health-professionals/management-cases-contacts.html.
 511 Accessed 25 May 2023.
- 512 24. Harrison LB, Bergeron G, Cadieux G, et al. Monkeypox in Montréal: epidemiology,
 513 phylogenomics, and public health response to a large North American outbreak. Ann Intern
 514 Med 2023; 176:67–76.
- 515 25. CDC. Safety Information for Monkeypox Vaccine | Vaccine Safety. 2024. Available at:
 516 https://www.cdc.gov/vaccinesafety/vaccines/Monkeypox-Vaccine.html. Accessed 3
 517 February 2024.
- 518 26. Mazzotta V, Lepri AC, Matusali G, et al. Immunogenicity and reactogenicity of modified
 519 vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox
 520 vaccine exposure and HIV infection: prospective cohort study. eClinicalMedicine 2024; 68.
 521 Available at: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00597522 7/fulltext. Accessed 3 February 2024.
- 523 27. Public Health Ontario. Mpox immunization and post-immunization cases in Ontario.
 524 Toronto, ON: 2023. Available at: https://www.publichealthontario.ca/525 /media/Documents/M/2022/mpx-immunization-post-ontario526 cases.pdf?rev=d5914e5a55a249d59a27e31c09a49305&la=fr. Accessed 16 November 2023.
- 527 28. Public Health Agency of Canada. Smallpox and mpox (monkeypox) vaccines: Canadian
 528 Immunization Guide. 2023. Available at: https://www.canada.ca/en/public529 health/services/publications/healthy-living/canadian-immunization-guide-part-4-active530 vaccines/page-21-smallpox-vaccine.html. Accessed 6 February 2024.
- 531 29. Hart TA, Moore DM, Noor SW, et al. Prevalence of HIV and sexually transmitted and
 532 blood-borne infections, and related preventive and risk behaviours, among gay, bisexual
 533 and other men who have sex with men in Montreal, Toronto and Vancouver: results from
 534 the Engage Study. Can J Public Health 2021; 112:1020–1029.
- 30. Harvey-Lavoie S, Apelian H, Labbé A-C, et al. Community-based prevalence estimates of
 Chlamydia trachomatis and *Neisseria gonorrhoeae* infections among gay, bisexual, and
 other men who have sex with men in Montréal, Canada. Sex Transm Dis 2021; 48:939–944.
- 538 31. Cox J, Apelian H, Moodie EEM, et al. Use of HIV pre-exposure prophylaxis among urban
 539 Canadian gay, bisexual and other men who have sex with men: a cross-sectional analysis of
 540 the Engage cohort study. CMAJ Open 2021; 9:E529–E538.
- 541 32. Doyle CM, Maheu-Giroux M, Lambert G, et al. Combination HIV Prevention Strategies
 542 Among Montreal Gay, Bisexual, and Other Men Who Have Sex with Men in the PrEP Era:
 543 A Latent Class Analysis. AIDS Behav 2021; 25:269–283.
- S44 33. CIHR Canadian HIV Tirals Network. CTN 300: The Engage Cohort Study | Prevention.
 S45 Available at: https://www.hivnet.ubc.ca/study/ctn-300-the-engage-cohort-study/. Accessed
 S46 8 February 2024.

- 547 34. Yauck M, Moodie EE, Apelian H, et al. General regression methods for respondent-driven
 548 sampling data. Stat Methods Med Res 2021; 30:2105–2118.
- 549 35. Daroya E, Grey C, Lessard D, et al. 'I did not have sex outside of our bubble': changes in
 550 sexual practices and risk reduction strategies among sexual minority men in Canada during
 551 the COVID-19 pandemic. Cult Health Sex 2022; 0:1–17.
- Skakoon-Sparling S, Palma PA, Zahran A, et al. Loneliness and the sexual behavior of
 sexual minority men in the context of the COVID-19 pandemic. Soc Personal Psychol
 Compass 2023; 17:e12814.
- 37. R Core Team. R: A Language and Environment for Statistical Computing. 2023; Available
 at: https://www.r-project.org/. Accessed 7 February 2024.
- Stan Development Team. RStan: the R interface to Stan. 2023; Available at: https://mc stan.org/. Accessed 16 November 2023.
- 39. Goodrich B, Gabry J, Ali I, Brilleman S. rstanarm: Bayesian applied regression modeling
 via Stan. 2023; Available at: https://mc-stan.org/rstanarm.
- 40. Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a
 global case series. The Lancet 2023; 401:939–949.
- Milwid RM, Xia Y, Doyle CM, et al. Past dynamics of HIV transmission among men who
 have sex with men in Montréal, Canada: a mathematical modeling study. BMC Infect Dis
 2022; 22:233.
- Mizushima D, Shintani Y, Takano M, et al. Prevalence of Asymptomatic Mpox among Men
 Who Have Sex with Men, Japan, January–March 2023 Volume 29, Number 9—
 September 2023 Emerging Infectious Diseases journal CDC. Available at:
 https://wwwnc.cdc.gov/eid/article/29/9/23-0541_article. Accessed 9 February 2024.
- 570 43. CDC. Monkeypox Technical Reports. 2023. Available at:
 571 https://www.cdc.gov/poxvirus/mpox/cases-data/technical-report/report-1.html. Accessed 16
 572 April 2024.
- Knight J, Tan DHS, Mishra S. Maximizing the impact of limited vaccine supply under
 different early epidemic conditions: a 2-city modelling analysis of monkeypox virus
 transmission among men who have sex with men. CMAJ 2022; 194:E1560–E1567.
- 576 45. Sachdeva H, Shahin R, Ota S, et al. Preparing for mpox resurgence: Surveillance lessons
 577 from outbreaks in Toronto, Canada. J Infect Dis 2023; 229:S305–S312.
- 46. Brousseau N, Carazo S, Febriani Y, et al. Single-dose effectiveness of mpox vaccine in
 Quebec, Canada: test-negative design with and without adjustment for self-reported
 exposure risk. Clin Infect Dis 2023; 78:461–469.

581 582	47.	Deputy NP, Deckert J, Chard AN, et al. Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. N Engl J Med 2023 ; 388:2434–2443.
583 584	48.	Sagy YW, Zucker R, Hammerman A, et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med 2023 ; 29:748–752.
585 586 587	49.	Bertran M, Andrews N, Davison C, et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. Lancet Infect Dis 2023 ; 23:828–835.
588 589 590 591	50.	Dalton AF. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morb Mortal Wkly Rep 2023 ; 72. Available at: https://www.cdc.gov/mmwr/volumes/72/wr/mm7220a3.htm. Accessed 11 February 2024.
592 593 594	51.	Rosenberg ES, Dorabawila V, Hart-Malloy R, et al. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022. MMWR Morb Mortal Wkly Rep 2023 ; 72:559–563.
595 596 597 598 599	52.	Navarro C, Lau C, Buchan SA, et al. Effectiveness of one dose of MVA-BN vaccine against mpox infection in males in Ontario, Canada: A target trial emulation. 2023; :2023.10.04.23296566. Available at: https://www.medrxiv.org/content/10.1101/2023.10.04.23296566v1. Accessed 11 February 2024.
600 601	53.	Eddelbuettel D, Francois R, Allaire J, et al. Rcpp: Seamless R and C++ Integration. 2023; Available at: https://CRAN.R-project.org/package=Rcpp.
602 603	54.	Li E, Guo X, Hong D, et al. Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus. Signal Transduct Target Ther 2023 ; 8:350.
604 605 606	55.	Sanz-Muñoz I, Sánchez-dePrada L, Sánchez-Martínez J, et al. Possible Mpox Protection from Smallpox Vaccine–Generated Antibodies among Older Adults. Emerg Infect Dis 2023 ; 29:656–658.
607 608 609	56.	WHO. Multi-country outbreak of mpox, External situation report#30 – 25 November 2023. Available at: https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox external-situation-report-3025-november-2023. Accessed 3 February 2024.
610		